Navigation Links
Medication Adherence Technology Combines with Patient Outreach Program to Yield Healthier Populations and Reduce Healthcare Costs
Date:10/20/2009

atient, caregiver and physician. Linking the patient, caregivers and medical team gives the patient a sense of accountability for their adherence levels and provides the physician with continuity of care.

For more information, visit www.PresentCare.com.

Look for PresentCare at the Connected Health Symposium, October 21 & 22 in Boston, MA. http://connected-health.org/events/symposium-2009.aspx

SOURCE PresentCare Inc.


'/>"/>
SOURCE PresentCare Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medication Telemonitoring Improves Compliance and Behavior in NIH Study
2. New Pleio Medication Adherence Service Increases Prescription Refills Up To 53%
3. Drug Interaction Tool Offered Free in Response to Increasing At-Home Deaths From Medication Errors
4. Family Medicine Cabinet: Free, New On-Line Tool Helps Track Your Medication Safety
5. Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications
6. North Dakota Pharmacists and Medication Management Systems Partner to Deliver Quality MTM Services to Patients With Diabetes
7. Prominent Physician Achieves Success Using Topical Sinus Medications via Pulsitile Irrigation
8. Pharmacy Students Taught Improved Medication Adherence and Holistic Health Services Through Program Incorporating InforMedixs Med-eXpert(TM) System
9. InnovationRx, a Prescription Adherence Solutions Company, and InforMedix Partner to Market and Sell End-to-End Medication Adherence Solutions
10. Artromick Aligns with McKesson to Enhance Medication Safety at the Patients Bedside
11. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and ... BAX ) today announced data from PERSIST-1 – a ... treatment of myelofibrosis – in a late-breaking oral session ... Society of Clinical Oncology (ASCO), May 29-June 2, 2015 ... an investigational oral multikinase inhibitor with specificity for JAK2 ...
(Date:5/29/2015)... 2015 In recent years, the biopharmaceutical industry ... Data that can generate valuable insights. Despite this, the ... Data have caused the biopharmaceutical sector to embrace Big ... According to a recent study by benchmarking firm, ... Big Data team or function in place; however, these ...
(Date:5/29/2015)... May 29, 2015 Asthma ... p ersonalized   treatments enter arena, says   ... Despite generic erosion facing several of the leading asthma ... fumarate) and Xolair (omalizumab), the global market for asthma ... end of the decade.   New analysis ...
(Date:5/29/2015)...  Caris Life Sciences® today announced the presentation ... utilized Caris Molecular Intelligence®, the company,s panomic, comprehensive ... in patients with colorectal and pancreatic cancer subtypes, ... protein 1 (PD-1) and its ligand, PD-L1. The ... American Society of Clinical Oncology Annual Meeting (ASCO) ...
Breaking Biology Technology:Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 2Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 4Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 5Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 6Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 7Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 8Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 9Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 10New Study Details Current & Future Big Data Trends Across Medical Affairs Functions 2Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 2Personalized Treatment for Severe Asthma to Drive Market Growth Despite Patent Expirations 3Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 2Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 3Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 4
... human immune system isnt ready for a war. , ... illness, but they take time to work. A new ... Foundation (OMRF) and Emory University stands to revolutionize the ... Nature, the researchers describe a method that can identify ...
... GPRO ) announced today that the Company will present ... May 6 at approximately,11:30 a.m. Eastern Time. The presentation ... through a link on the investors section of Gen-Probe,s,website ... for 30,days following the event., About Gen-Probe, ...
... LeMaitre,Vascular, Inc. (Nasdaq: LMAT ), a provider ... results for Q1 2008. Q1 2008,revenues were $11.8 ... Q1 2008 revenues increased 5% in the ... its vascular category, while general,surgery revenues decreased 4%. ...
Cached Biology Technology:The most natural drug 2Gen-Probe to Webcast Presentation at Deutsche Bank 33rd Annual Health Care Conference 2LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 2LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 3LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 4LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 5LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 6LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 7LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 8LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 9LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 10LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 11
(Date:5/20/2015)... , May 20, 2015 NXT-ID, Inc. (NASDAQ: ... its wholly owned subsidiary, 3D-ID LLC, a company engaged ... Battelle for the biometrics technology portion of the recently ... from the Department of the Army. 3D-ID ... developed for government, law enforcement and security agencies. ...
(Date:5/14/2015)... , May 14, 2015 Research and Markets ... the "Fingerprint Sensors Market in Smart Mobile Devices ... report believes that 2014 was a watershed year for ... introduction of ,Apple Pay,. Apple gave fingerprint sensors a ... payment service. Fingerprint sensors are a must-have feature in ...
(Date:5/10/2015)... GOTHENBURG, Sweden , May 11, 2015 ... touch fingerprint sensors FPC1025 and FPC1155 from the distributor World ... one of FPC,s distributors in Asia . ... the sensors will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of + 1 000 ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
... the global pandemics of obesity and diabetes, poses a ... progress, there is still much to be done to ... In Europe, as many as one-half of patients are ... managing dyslipidaemias offer new hope.3,4 Experts from the European ...
... depends on the ability of the plant cover to intercept ... of leaf area, the architecture of the vegetation cover, and ... crop,s ability to capture light energy is the leaf area ... was defined as the ratio of leaf area to a ...
... cell that participates in the repair of the large airways ... the body from infectious agents and toxins in the environment. ... clearing mucus from the airways. The mucus is largely produced ... of normal and excessive mucus production are not well understood. ...
Cached Biology News:First joint ESC/EAS guidelines for the management of dyslipidaemias 2First joint ESC/EAS guidelines for the management of dyslipidaemias 3First joint ESC/EAS guidelines for the management of dyslipidaemias 4New non-destructive method to estimate leaf area index in vegetables 2UCLA stem cell scientists discover new airway stem cell 2
... ,,GenScript offers many antibody modification ... fragmentation. Labeling antibodies with biotin and ... quantitation of the target molecule. In ... use only the antigen-binding (Fab) portion ...
...
Attoglow Western Blot Enhancing Kit contains Millennium Enhancer which can significantly boost Western blot signals, and is compatible with other enhancing mechanisms to achieve multiplied enhancing ...
Request Info...
Biology Products: